Results & Financial lifeHealthcare - Pharma - Biotech
OSE Immunotherapeutics Reports Additional Positive Results of Combi-TED Phase 2 Randomized Trial with Tedopi® (OSE2101) in metastatic Non-Small Cell Lung Cancer
29/10/2026 17:30
AMFImmediate publication
Cappuzzo, MD, PhD, on October 25, 2026, at the Annual Meeting of the European Society for Medical Oncology (ESMO) in Madrid
OSE Immunotherapeutics Reports Additional Positive Results of
Combi-TED Phase 2 Randomized Trial with Tedopi® (OSE2101)
in metastatic Non-Small Cell Lung Cancer
- Final positive readout for primary and several secondary endpoints presented by Federico
Cappuzzo, MD, PhD, on October 25, 2026, at the Annual Meeting of the European Society for Medical Oncology (ESMO) in Madrid
- 12-month OS rate and median OS point in favour of combining Tedopi® with chemotherapy docetaxel or immunotherapy nivolumab
- OSE Immunotherapeutics to host a KOL webcast on November 4, 2026
Nantes, France, October 29, 2026 – 6:00pm CET – OSE Immunotherapeutics SA (ISIN: FR0012127173;
Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immunooncology and immuno-inflammation, today reported final positive results from the Combi-TED academic
Phase 2 international clinical trial of Tedopi® after an oral presentation at the ESMO 2026 Annual Meeting.
The study was sponsored by FoRT and evaluated Tedopi® (OSE2101), in combination with either chemotherapy or anti-PD1, as a 2nd line treatment in 106 patients with metastatic Non-Small Cell Lung
Cancer (NSCLC).
Federico Cappuzzo, MD, PhD, Director of Medical Oncology at the National Cancer Institute Regina Elena
(Rome, Italy) and Lead Investigator of the trial, commented: “I am very excited with the results of the Combi-
TED phase 2 study, in which Italy, France and Spain participated actively. The overall survival observed when combining Tedopi® with docetaxel or nivolumab is a strong signal suggesting that outperforming docetaxel in this hard-to-treat population, with an acceptable safety profile, may finally be achieved. We are now eager to see what Tedopi® will do as a monotherapy versus docetaxel in the ongoing ARTEMIA phase 3 trial.”
Combi-TED is an open label, randomized, three-arm Phase 2 study evaluating Tedopi® in combination with docetaxel (n = 36) or the anti-PD1 immune checkpoint inhibitor nivolumab (Opdivo®; n = 35), or docetaxel alone (reference arm; n = 35) as second-line treatment in 106 HLA-A2 positive patients with metastatic
NSCLC and no evidence of EGFR mutations or ALK or ROS1 rearrangement, after first-line chemoimmunotherapy.
In each study arm, patients were treated every 3 weeks for up to 6 cycles. Docetaxel was dosed at 60mg/m² when combined with Tedopi® and 75mg/m² in the reference arm. From cycle 7 onward, Tedopi® was administered every 6 weeks until 12 months, then every 12 weeks. Nivolumab continued every 3 weeks in the combination arm with Tedopi®. Treatment continued according to protocol until progression, unacceptable toxicity, patient refusal or a maximum of 6 cycles for docetaxel alone.